<DOC>
	<DOCNO>NCT02407054</DOCNO>
	<brief_summary>The main purpose study evaluate safety effectiveness study drug know LY3023414 combination enzalutamide men prostate cancer .</brief_summary>
	<brief_title>A Study Enzalutamide LY3023414 Men With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate . Metastatic disease document positive bone scan metastatic lesion compute tomography ( CT ) magnetic resonance imaging ( MRI ) scan . Prostate cancer progression document PSA and/or radiographic progression accord prostate cancer work group 2 ( PCWG2 ) . Prior abiraterone treatment complete least 4 week prior cycle 1 day 1 . Surgically medically castrate , testosterone level &lt; 50 nanograms/deciliter . Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 1 . Ability swallow study drug whole . Adequate hematologic function . Adequate coagulation parameter , define international normalization ratio ( INR ) ≤ 2 . Availability tumor tissue time since diagnosis prostate cancer disease . If tumor sample available participant might still eligible follow discussion investigator medical monitor . Prior cytotoxic chemotherapy , immunotherapy , PI3K/AKT/mTOR agent ( include TORC1 TORC2 inhibitor ) , RA 223 dichloride treatment castration resistant prostate cancer ( CRPC ) . Participants may receive docetaxel hormonesensitive setting . Prior investigational new generation potent antiandrogen therapy ( ARN 509 ) . Prior treatment enzalutamide . Pathological find consistent small cell carcinoma prostate . Prior systemic treatment azole drug ( fluconazole , itraconazole ) within 4 week cycle 1 day 1 . Known brain metastasis . History ( ) seizure condition may predispose seizure ( prior cortical stroke significant brain trauma ) ; ( b ) loss consciousness transient ischemic attack within 12 month prior day 1 cycle 1 . Uncontrolled hypertension ( systolic blood pressure [ BP ] ≥ 160 millimeter mercury [ mmHg ] diastolic BP ≥ 95 mmHg ) . Have serious preexist medical condition ( discretion investigator ) . Have know acute chronic leukemia current hematologic malignancy , judgment investigator sponsor , may affect interpretation result . Have insulindependent diabetes mellitus . Participants type 2 diabetes mellitus eligible adequate control blood glucose level obtain oral antidiabetic document hemoglobin A1c &lt; 7 % . Presence active gastrointestinal disease condition interfere significantly absorption , distribution , metabolism , excretion oral therapy ( e.g . ulcerative disease , uncontrolled nausea , vomit , grade ≥2 diarrhea , malabsorption syndrome ) . Have history New York Heart Association ( NYHA ) Class ≥3 , QTc interval &gt; 450 millisecond ( m ) screen electrocardiogram ( ECG ) per Friderica 's formula , unstable angina , myocardial infarction ( MI ) 6 month prior study drug administration . Clinically significant electrolyte imbalance ≥ grade 2 . Currently receive treatment therapeutic dos warfarin sodium . Have initiate treatment bisphosphonates approve receptor activator nuclear factor kappaB ligand ( RANKL ) target agent ( e.g . denosumab ) ≤28 day prior day 1 cycle 1 . Concurrent serious infection require parenteral antibiotic therapy . Have second primary malignancy judgment investigator medical monitor may affect interpretation result . Have active , known fungal , bacterial , and/or know viral infection .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>